Oved Amitay is Vice President, Head of Commercial at Alnylam Pharmaceuticals (NASDAQ: ALNY; MKT CAP>$7.0 B). Alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery known as RNA interference. RNAi technology provides an opportunity to treat diseases and impact the lives of patients by silencing disease-causing genes. Mr. Amitay is responsible for the company’s commercial strategy and its implementation, focused on building the organization for executing the goal of commercializing 3 genetic medicine products by 2020.
Before joining Alnylam in 2012, Mr. Amitay was Vice President, Strategic Development at Genzyme Corporation, now a Sanofi company, and led the internal research and development activities for the rare diseases business. Prior to that position, he was General Manager of the Gaucher Disease and MPS Portfolios at Genzyme, where he was responsible for the flagship product Cerezyme®, and led it to peak sales of over $1.2 billion. He also oversaw the development of the drug Eliglustat, which had recently been approved by the FDA and EMA. Mr. Amitay joined Genzyme in 1998 and held positions of increasing responsibility in regulatory affairs, marketing, and business development in Europe and the Middle East. Prior to joining Genzyme, he was a staff pharmacologist at Peptor Ltd. (Israel) and Cambridge NeuroScience, Inc. (MA, USA), where he was involved in early stage drug development programs. He is frequently invited to speak on topics related to orphan drugs and commercialization of therapies for patients with rare diseases.
Mr. Amitay is a registered pharmacist, trained at the School of Pharmacy, Hebrew University in Jerusalem, and the graduate program in Pharmacology at Northeastern University in Boston. He has a certificate from the program for Critical and Creative Thinking at the University of Massachusetts. Mr. Amitay also has more than twenty years of leadership experience as an officer in the Israeli Defense Forces.